Peer Exchange

A panel of expert oncologists have a detailed discussion on emerging biomarkers, molecular testing strategies, and the evolving targeted treatment landscape in non–small cell lung cancer.

Thomas Herzog, MD, Thomas Krivak, MD, and Ian Hagemann, MD, PhD discuss the biological mechanisms behind homologous recombination deficiency (HRD) in ovarian cancer and expand on best practices for somatic and germline HRD testing and results-based patient management in the clinic.

An expert panel of gynecologic oncologists reviews recent data from the 2023 ASCO Annual Meeting and discusses the evolving treatment landscape.

A panel of experts summarizes the current treatment landscape for early and metastatic HER2+ breast cancer and discusses recent data updates in these settings, including those presented at the 2023 American Society of Clinical Oncology (ASCO) meeting.

Moderator Zofia Piotrowska, MD, MHS introduces an upcoming Onclive Peer Exchange discussion with expert panelists concerning recent updates from in the diagnosis and treatment of EGFR Mutant NSCLC.

Experts review recent updates in the treatment of HCC and discuss how evidence from clinical trials and real-world settings can be applied to clinical practice to improve patient outcomes.

Following the 2023 ASCO Annual Meeting, experts on HR+/HER2- breast cancer discuss the evolving treatment landscape and data updates on frontline and later-line therapies.

Expert oncologists review recent updates in the treatment landscape of prostate cancer and consider how data will impact their own practice.

Expert panelists review data presented at ASCO 2023 and surrounding meetings to elucidate the current treatment landscape of renal cell carcinoma.

Centering discussion on several patient scenarios, expert panelists review recent clinical data and consider how it has impacted their management of patients with small cell lung cancer (SCLC).

An expert perspective pertaining to treatment advances in early-stage non-small cell lung cancer and how to best apply data from ASCO 2023 into daily practice.

Moderator Michael Bishop, MD leads a discussion with panelists Hannah Choe, MD, Doris M. Ponce, MD, and Bart L Scott, MD, concerning recent updates in the prevention, diagnosis, and treatment of Graft-Versus-Host Disease.

Moderator Naval G. Daver, MD leads a discussion with panelists Amir Fathi, MD, Margaret T. Kasner, MD, Eunice S. Wang, MD, providing an overview of AML pathogenesis and molecular subtypes, standard-of-care treatment approaches, and emergent therapies.

A panel of experts review several updates in myelodysplastic syndromes (MDS) that were presented at ASCO 2023 and other recent meetings and discuss how the data may change treatment approaches in clinical practice.

Expert panelists reflect on the current state of molecular testing and management in patients with metastatic colorectal cancer, reviewing recent clinical data and considering changes in real-world practice.

Key opinion leaders review recent clinical data in the field of multiple myeloma management and consider how the treatment paradigm has evolved.

Experts discuss several recent data updates in the treatment of myeloproliferative neoplasms (MPNs) and the impact on clinical practice.

Expert panelists review recent updates in the management of relapsed/refractory diffuse large B-cell lymphoma and consider how they have impacted the real-world treatment landscape and clinical practice.

Sponsored in part by Regeneron. Content independently created by OncLive.

A panel of experts discuss updates in immunotherapy for advanced non-small cell lung cancer (NSCLC) and the impact of recent clinical trial data on treatment decision-making.

Key opinion leaders in the field of non–small cell lung cancer reflect on the evolving role of immunotherapy, alone or in combination, within various subsets of disease.

Centering discussion on clinical scenarios, expert oncologists work together to review updates in the treatment of differentiated thyroid cancer (DTC) that were presented at key conferences in 2022.

A panel of expert oncologists consider the role of HER2 expression in colorectal cancer and review novel targeted therapies in this setting.

Expert panelists reflect on the evolving treatment landscape of urothelial carcinomas and identify how it has impacted their real-world practices.

Expert panelists review updated data in the identification and management of resectable cutaneous squamous cell carcinoma and reflect on how real-world practice has evolved.

A panel of experts discuss data from recent clinical trials in renal cell carcinoma (RCC) presented at ASCO GU 2023 and other meetings, and its potential impact on clinical practice.

Expert panelists review new data on treatment and management of nmCRPC, mHSPC, and mCRPC and consider how these data may impact clinical practice.

Expert panelists review patient case studies and discuss key updates in the treatment landscape of advanced HCC from the 2023 ASCO Gastrointestinal Cancers Symposium and beyond.

A panel of experts review the evolving treatment landscape of biliary tract cancers contextualized with their real-world experiences.

An expert panel reviews the diagnosis and treatment of metastatic colorectal cancer with a focus on the setting of HER2-positive disease.

Expert perspectives on the evolving treatment landscape of HR+ breast cancer and how novel therapies have been incorporated in practice.